Store Fat or Burn It? Targeting a Single Protein Flips the Switch

As obesity becomes a growing issue worldwide – nearly tripling over the last-half century – scientists are trying to gain a better understanding of the condition at the molecular level. Now, new research led by UC San Francisco scientists suggests that a single protein could play an outsized role in

Pandemic Brings Career Setbacks for Women in Medicine

Women in academic medicine are facing the prospect of career setbacks as a result of the COVID-19 pandemic. Katherine Van Loon, MD, MPH, Associate Professor of Clinical Medicine and Director of the HDFCCC Global Cancer Program; and Bridget Keenan, MD, PHD, a Clinical Fellow of Hematology/Oncology

‘AutoImmunoprofiler’ Builds on Success in Cancer Research to Advance Treatments for Autoimmune Diseases

UC San Francisco scientists have formed a research alliance with pharmaceutical firm Eli Lilly and Company aimed at better understanding autoimmune diseases and fostering the development of new therapies. Based on the innovative Immunoprofiler model launched at UCSF in 2017, the new initiative

New Test Predicts Tumors Most Likely to Respond to Radiation, Chemotherapy

Many cancer patients might respond better to treatments with the help of a new prognostic indicator based on a distinctive pattern of gene activity within tumor cells, according to a new study of human cancer data and experiments on human cancer cell lines grown in the lab. The new research, led by

Millie Hughes-Fulford, the First Woman Scientist in Space, Dies at 75

Millie Hughes-Fulford, PhD, a UC San Francisco scientist who flew in June 1991 aboard the first space shuttle mission dedicated to biomedical studies, died Feb. 2 at the age of 75. She was the first woman to fly as a NASA payload specialist and was part of the first crew to include three women. On

Response to Cancer Immunotherapy May Be Affected by Genes We Carry from Birth

For all their importance as a breakthrough treatment, the cancer immunotherapies known as checkpoint inhibitors still only benefit a small minority of patients, perhaps 15 percent across different types of cancer. Moreover, doctors cannot accurately predict which of their patients will respond. A

Camp Okizu, a Refuge for Families Affected by Childhood Cancer, Pledges to Rise from the Ashes

In September, the North Complex West Zone fire ripped through Butte County, killing 16 residents and decimating more than 2,000 structures. The structures destroyed in the blaze included almost all of the cabins, bathrooms and main buildings that make up Okizu – a 500-acre refuge for families of